Eighth Circuit addresses duty to update and scheme liability *

USA - June 11 2012
In Public Pension Fund Group, et al. v. KV Pharmaceutical Company, et al. (No. 10-3402, June 4, 2012), the United States Court of Appeals for the Eighth Circuit reversed a lower court’s dismissal of a securities fraud class action brought under the Private Securities Litigation Reform Act (the “PSLRA”).

Matrixx Initiatives, Inc. v. Siracusano *

USA - March 25 2011
Failure to disclose a statistically insignificant incidence of adverse side effects could lead to significant securities-fraud liability for publicly traded drugmakers, device manufacturers, and others under a recent Supreme Court decision.

Co-authors: Eric R. Sherman, J David Jackson.

Merck & Co. v. Reynolds – US Supreme Court holds “inquiry notice” insufficient to trigger statute of limitations for securities fraud claims *

USA - May 4 2010
Would-be plaintiffs may have more time to pursue federal securities law class actions against publicly held companies under a new decision from the U.S. Supreme Court.

Co-authors: Eric R. Sherman.